openPR Logo
Press release

Diabetic Macular Edema Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent and Other Developments

05-25-2017 06:58 PM CET | Health & Medicine

Press release from: P&S Market Research - Pharmaceuticals

Diabetic Macular Edema Therapeutics Pipeline Analysis, 2017 -

As estimated worldwide in 2011, the number of peoples with diabetes were around 346 million and its number is unceasingly getting bigger. It is expected to be double in number by 2030. Diabetic retinopathy and diabetic macular edema is occurring, which leads to the vision loss. These adverse conditions mostly occur in patient having high blood sugar level and high blood pressure. Therefore, the consequential increase in growth of diabetic macular edema therapeutics pipeline is observed.

Explore Report at: www.psmarketresearch.com/market-analysis/diabetic-macular-edema-therapeutics-pipeline-analysis

Diabetic macular edema became the foremost cause of vision loss in diabetic patients and working-aged adults. Diabetic macular edema is generally a building up of fluid in macula region in retina, which is present at the back of the eye and responsible for making sharp and straight-headed vision with macula. Swelling and thickening of macula majorly affecting vision by distorting it. The accumulation of fluid causes the leakage which can damage the blood vessels present near retina. The foremost cause of diabetic macular edema is diabetic retinopathy, but in some cases, it can subsequently occur after an eye surgery. It is also found that inflammation in eye can cause diabetic macular edema. Theprimary symptoms of diabetic macular edema is the wavy or blurred vision, in which colour may be faded. If it occurs to only one eye, the blurry vision will not be noticed until the condition become severe.

Request for Table of Content at: www.psmarketresearch.com/market-analysis/diabetic-macular-edema-therapeutics-pipeline-analysis/toc-sample

In March 2016, F Hoffmann-La Roche AG, Inc. started a Phase II clinical study on drug RO6867461, in participants with center-involving Diabetic macular edema. In November 2016, Regeneron Pharmaceuticals, Inc. started a Phase IIIb of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intravitreal injections to subjects with Diabetic Macular Edema.

Browse Other Related Report at: www.psmarketresearch.com/industry-report/pharmaceuticals

Some of the companies having a pipeline of diabetic macular edema therapeutics include Regeneron Pharmaceuticals, Inc., Bayer AG, Allergan, Clearside Biomedical, Inc., Novartis AG, Chengdu Kanghong Biotech Co., Ltd., ThromboGenics NV, F Hoffmann-La Roche AG, Boehringer Ingelheim GmbH, Valeant Pharmaceuticals International, Inc.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Kundan
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: www.psmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Diabetic Macular Edema Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent and Other Developments here

News-ID: 552218 • Views:

More Releases from P&S Market Research - Pharmaceuticals

Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments
Psoriasis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Paten …
The study analyzed that the psoriasis therapeutics pipeline comprises approximately 150 drug candidates in different stages of development. Psoriasis is a chronic inflammatory disorder that causes red patches covered with white scales on the skin. It is characterized when a person’s immune system sends defective signals which results in skin cells to grow rapidly. The body does not shed these excess skin cells and pile up on the surface of
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
Diabetic Foot Ulcer Therapeutics Pipeline Projects Immense Growth Ahead
The study analysed that the diabetic foot ulcer pipeline comprises of approximately 27 drug candidates in different stages of development. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/diabetic-foot-ulcers-therapeutics-pipeline-analysis Diabetic foot ulcer is a serious complication of diabetes and can be defined as the ulceration in foot along with neuropathy or peripheral artery disease of the lower limb in diabetic patients. Diabetic foot ulcer is categorized into two types namely; neuropathic foot where
Technological Advancements at Cellular and Molecular Level Strengthening the IgA Nephropathy Pipeline
Technological Advancements at Cellular and Molecular Level Strengthening the IgA …
The pipeline involves drug candidates that are being developed using specific targets such as a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BlyS). More than three drug candidates are being developed using subcutaneous route of administration. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/iga-nephropathy-pipeline-analysis The study analyzed that the IgA nephropathy therapeutics pipeline comprises of 24 drug candidates in different stages of development. The report also includes epidemiology forecast for IgA Nephropathy for the
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/idiopathic-pulmonary-fibrosis-therapeutics-market As per the findings of research, it

All 5 Releases


More Releases for Diabetic

Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report. On the basis of
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025. To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282 Global Diabetic Socks Market: Factors Impacting the Market The primary factors driving the growth of the global diabetic socks market are increasing
Expanding Diabetic Populace Driven Growth For Diabetic Food Market Globally
Market Overview Diabetic Food items are dietary items that incorporate diminished starch and sugar substance that assistance in controlling the ascent of the blood glucose. Diabetic Food additionally contains low calorie sweeteners, slim down refreshments, and so on. These items are devoured by diabetic individuals and by the general population who are not diabetic as careful step to avoid diabetes. Diabetic nourishment makers are entering into different market fragments by presenting
Global Diabetic Footwear Market Is Driven By Growing Diabetic Patients Worldwide
Global Diabetic Footwear Market Report, published by Variant Market Research, forecast that the global market is expected to reach $9.4 Billion by 2024 from $5.3 Billion in 2016; growing at a CAGR of 7.4% from 2016 to 2024. To browse the complete report, visit at https://www.variantmarketresearch.com/report-categories/consumer-goods/diabetic-footwear-market Diabetic footwears are used to reduce foot amputation and ulceration risk in people suffering from diabetes. It is a lifestyle disease. Foot ulceration and debilitating
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be